Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

22.34 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Alkermes Plc

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results
From Business Wire News Releases
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
From PR Newswire
Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences
From Business Wire News Releases
How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference
From Business Wire News Releases
Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder
From Business Wire News Releases
Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at The NASDAQ OMX 31st Investor Program
From Business Wire News Releases
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference
From Business Wire News Releases
Alkermes plc Reports Third Quarter 2014 Financial Results
From Business Wire News Releases
Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results
From Business Wire News Releases
Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
From Business Wire News Releases
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference
From Business Wire News Releases
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain
From Business Wire News Releases
Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia
From Business Wire News Releases
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc.
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
Alkermes plc Reports Second Quarter 2014 Financial Results
From Business Wire News Releases
Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder
From Business Wire News Releases
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results
From Business Wire News Releases
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis
From Business Wire News Releases
Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates
From Business Wire News Releases
Clinical Trial Data, NDA Submissions, and Board Changes - Analyst Notes on Alkermes, Cubist, Repligen, Flamel Technologies and Chimerix
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting
From Business Wire News Releases
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.